Aspen to divest two oncology joint ventures to Strides
This article was originally published in Scrip
Executive Summary
Strides Arcolab is to acquire a 100% interest in its equally-owned oncology joint ventures with South Africa's Aspen Pharmacare for $117 million, as part of a restructuring effort.